Abstracts Archive - Page 495 of 2605 - ACR Meeting Abstracts

Abstract Number: PP08 • ACR Convergence 2023
Finding Gratitude in Adversity: The Impact of Finding the Right Rheumatologist
Yaideliz Acevedo, Global Healthy Living Foundation, Newark, NJ
Background/Purpose: I recall sitting in the doctor's office with my one-month-old baby in his stroller, hearing the words "You have rheumatoid arthritis." At 21, I…
Abstract Number: PP01 • ACR Convergence 2023
You Can’t Get This from a Doctor: The Role of Support Groups for Adults Aged 25-55 Living with Arthritis
Eileen Davidson, Global Healthy Living Foundation, Burnaby, BC, Canada
Background/Purpose: Living with a rheumatic condition comes with unique concerns specific to mental and social health like struggling with fatigue, anxiety, depression, and isolation, all…
Abstract Number: PP14 • ACR Convergence 2023
Putting Lived Experience into Action: Flipping the Script on Living with a Chronic Disease
Natasha Trehan¹ and Naomi Abrahams², ¹University of Ottawa, Take a Pain Check Foundation, Toronto, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Naomi was diagnosed with Juvenile Idiopathic Arthritis (JIA) at the age of 18, after enduring 3 years of misdiagnoses. Similarly, Natasha received a diagnosis…
Abstract Number: 2604 • ACR Convergence 2023
Premature Vascular Smooth Muscle Cells Senescence Driven by Interleukin-6-Mitochondrial STAT3-Mitofusin 2 Signaling in Takayasu’s Arteritis
Chenglong Fang¹, Lihong Du¹, Lili Li², Yuexin Chen³, Zuoguan Chen⁴, Yongjun Li⁴, Jing Li¹, Mengtao Li⁵, xiaofeng Zeng⁶ and Xinping Tian⁵, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ²The State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing, China, ³Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ⁴Department of Vascular Surgery, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China, ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁶Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Takayasu’s arteritis (TAK) is characterized by persistent vascular inflammation involving aorta and its main branches, which is an important prosenescent factor that in turn…
Abstract Number: PP09 • ACR Convergence 2023
Practicing Mindfulness to Improve Quality of Life
Vanessa Patino-Lydia, Global Healthy Living Foundation, Hallandale, FL
Background/Purpose: I’ve been living with symptoms of PSA and fibromyalgia for over 15 years. Four years ago, after flareup that severely impacted my mobility where…
Abstract Number: 2482 • ACR Convergence 2023
Preinflammatory Mesenchymal (PRIME) Cell Signature Genes Enrichment Predicts Treatment Response and Joint Prognosis in Rheumatoid Arthritis
Takayuki Fujii¹, Dana Orange², Caryn Hale², Koichi Murata¹, Hideo Onizawa¹, Akira Onishi¹, Masao Tanaka³, Akio Morinobu⁴ and Shuichi Matsuda⁵, ¹Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Rockefeller University, New York, NY, ³Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: This study aimed to determine predictors of treatment response and radiographic progression following the initiation of biological disease-modifying antirheumatic medications (bDMARDs) in patients with…
Abstract Number: PP03 • ACR Convergence 2023
Lupus with Slime: Improve QOL and Increase ROM in SLE with Slime
Amanda Greene, Los Angeles, CA
Background/Purpose: In 1983, over forty years ago, I was diagnosed with Systemic Lupus Erythematosus (SLE). I was immediately prescribed high dose corticosteroids. My body and…
Abstract Number: 2263 • ACR Convergence 2023
Disease Activity Progression in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)
Eric Morand¹, Richard Furie², Christine Peschken³, Martin Aringer⁴, Laurent Arnaud⁵, Barnabas Desta⁶, Tina Grünfeld Eén⁷, Alessandro Sorrentino⁸, Stephanie Chen⁹ and Bo Ding⁷, ¹Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ²Northwell Health, Manhasset, NY, ³University of Manitoba, Winnipeg, MB, Canada, ⁴Carl Gustav Carus, Dresden, Germany, ⁵University Hospitals of Strasbourg, Strasbourg, France, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁷BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁸Medical Affairs, AstraZeneca, Cambridge, United Kingdom, ⁹BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: The international, multicenter SLE Prospective Observational Cohort Study (SPOCS) collected data on patients with SLE in relation to their type 1 interferon gene signature…
Abstract Number: 2249 • ACR Convergence 2023
Bimekizumab-Treated Patients with Active PsA Showed Sustained Improvement in Disease Symptoms Assessed by the PsA Impact of Disease (PsAID)-12 Questionnaire: 1-Year Results Reported from Two Phase 3 Studies
Dafna Gladman¹, Laura Coates², Maarten de Wit³, Alexis R Ogdie⁴, Ana-Maria Orbai⁵, Barbara Ink⁶, Vanessa Taieb⁷, Jérémy Lambert⁸ and Laure Gossec⁹, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Oxford, Oxford, United Kingdom, ³Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Colombes, France, ⁸UCB Pharma, Irigny, France, ⁹Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: The PsA Impact of Disease‑12 (PsAID‑12) questionnaire is a patient (pt)-reported outcome measure assessing the impact of PsA on 12 physical, social, and psychological…
Abstract Number: PP13 • ACR Convergence 2023
My Four Pillars of Wellness: How Sleep, Diet, Exercise and Stress Reduction Enable Me to Define My Life and not let Sjögren’s Define Me
Lisa Rubenstein, Sjögren's Foundation, Los Angeles, CA

Background/Purpose: Being diagnosed with Sjögren’s has been a life changing event for me.I was diagnosed in 2013 after suffering from various odd ailments. Ultimately, extreme…
Abstract Number: 2478 • ACR Convergence 2023
Effect of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs on the Antibody Response to Four Doses of COVID-19 mRNA Vaccines in Children with Autoimmune and Rheumatic Diseases
Janna Shapiro¹, Florence Choi², Amy Xu³, Trang Duong⁴, Anne-Claude Gingras⁵, Sasha Bernatsky⁶, Susanne (Susa) Benseler⁷ and Rae Yeung⁸, ¹University of Toronto, Toronto, ON, Canada, ²Hong Kong Hospital Authority, Hong Kong, Hong Kong, ³Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health, Toronto, ON, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Children with rheumatic and autoimmune diseases are often treated with conventional or biologic disease-modifying antirheumatic drugs (cDMARDs and bDMARDs) to control disease. While effective,…
Abstract Number: 2272 • ACR Convergence 2023
Age and Race-Based Differences in Emergency Department Utilization for Systemic Lupus Erythematosus in the United States
Rashmi Dhital¹, Ioannis Karageorgiou², Ashbina Pokharel³ and Kenneth Kalunian⁴, ¹UC San Diego, San Diego, CA, ²William Beaumont University Hospital, Troy, MI, ³William Beaumont University Hospital, Royal Oak, MI, ⁴University of California San Diego, La Jolla, CA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) frequently visit the emergency department (ED) due to the complex disease course. Previous research highlights infection and pain…
Abstract Number: 2211 • ACR Convergence 2023
A Two-year Comparison of Back Pain and Morning Stiffness in Axial Spondyloarthritis and Non-axial Spondyloarthritis Chronic Back Pain Patients in the Spondyloarthritis Caught Early (SPACE) Cohort
Ana Bento da Silva¹, Miranda Van Lunteren², Mary Lucy marques³, Karen Fagerli⁴, Sofia Ramiro⁵, Désirée van der Heijde⁵ and Floris Van Gaalen², ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ³Leiden University Medical Center; Centro Hospitalar e Universitário de Coimbra (Department of Rheumatology), Coimbra, Portugal, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Treatment of axial spondyloarthritis (axSpA) has been shown to improve symptoms of the disease such as back pain (BP) and morning stiffness (MS). As…
Abstract Number: 2244 • ACR Convergence 2023
Switching Between Biologics and Targeted Synthetic Therapies Due to Inefficacy in Psoriatic Arthritis
Dalifer Freites Núñez¹, Maria Rodriguez Laguna¹, Cristina Hormigos martín¹, zulema Rosales², Leticia Leon³, Gloria Candelas¹, Daniel Rubio⁴, Jose Otazu¹, Benjamin Fernandez¹ and lydia Abasolo², ¹Hospital Clinico San Carlos, Madrid, Spain, ²Hospital Clínico San Carlos, Madrid, Spain, ³Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, ⁴Complutense University, Madrid, Spain
Background/Purpose: Biological and targeted synthetic therapies (ts/bDMARDs) have transformed the management ofPsoriatic arthritis (PsA).However, PsA might experience ts/bDMARD failure, (mainly due to inefficacy), and switching…
Abstract Number: 2239 • ACR Convergence 2023
Achievement of Disease Control in PsA Patients Treated with Upadacitinib at Week 152: Post Hoc Analysis of the Long-term Extensions of Two Phase 3 Trials
Arthur Kavanaugh¹, Kristi Mizelle², Oliver FitzGerald³, Enrique Soriano⁴, Peter Nash⁵, Sandra Ciecinski⁶, Limei Zhou⁶, Arathi Setty⁶ and Laure Gossec⁷, ¹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ²Tidewater Physicians Multispecialty Group, Newport News, VA, ³Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁴Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵School of Medicine, Griffith University, Brisbane, Australia, ⁶AbbVie, Inc., North Chicago, IL, ⁷Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: A main goal of therapy for patients (pts) with PsA is to achieve and maintain the lowest possible level of disease activity across domains.1…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].